Contact Us
Drug Search Results
More Filters [+]

Somatostatin

Alternative Names: somatostatin
Latest Update: 2024-07-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: SSTR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Italy | Jordan | Korea | Luxembourg | Malta | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: BCN Peptides
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Somatostatin

Countries in Clinic: Hungary, Lithuania, Poland, Russia, Serbia, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acromegaly|Carcinoid Tumor

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT02795858

P2

Active, not recruiting

Carcinoid Tumor

2022-12-31

ISIS 766720-CS3

P2

Completed

Acromegaly

2022-03-31

24%
ISIS 766720-CS3

P2

Completed

Acromegaly

2022-03-31

24%

Recent News Events

Date

Type

Title

07/25/2024

News Article

 Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma

07/18/2024

News Article

 Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

07/15/2024

News Article

 Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

07/10/2024

News Article

 Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions